Emend Intravenous and Pioglitazone and Glimepiride Tablets
Determining the interaction of Emend Intravenous and Pioglitazone and Glimepiride Tablets and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Fosaprepitant may reduce the blood levels and effects of glimepiride. Contact your doctor if your symptoms worsen or your condition changes during treatment with these medications. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: Coadministration with aprepitant or its prodrug, fosaprepitant, may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 2C9. The mechanism is accelerated clearance due to induction of CYP450 2C9 activity by aprepitant. According to the manufacturer, coadministration of aprepitant (125 mg single dose on day 1 and 80 mg/day on days 2 and 3) and the CYP450 2C9 substrate tolbutamide (500 mg orally prior to initiation of aprepitant and on days 4, 8 and 15) resulted in a decrease in tolbutamide systemic exposure (AUC) by 23% on day 4, 28% on day 8, and 15% on day 15. Similarly, healthy subjects stabilized on chronic warfarin therapy given the same regimen of aprepitant had a 34% decrease in S(-) warfarin trough concentration accompanied by a 14% decrease in the INR five days after completion of aprepitant dosing. However, there was no effect on the AUC of R(+) and S(-) warfarin determined on day 3.
MANAGEMENT: Caution is advised if aprepitant or fosaprepitant must be used concomitantly with medications that undergo metabolism by CYP450 2C9, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever aprepitant or fosaprepitant is added to or withdrawn from therapy.
- "Product Information. Emend (aprepitant)." Merck & Company Inc, West Point, PA.
Generic Name: fosaprepitant
Brand name: Emend for Injection
Synonyms: Fosaprepitant
Generic Name: glimepiride / pioglitazone
Brand name: Duetact
Synonyms: Glimepiride and pioglitazone, Pioglitazone and Glimepiride
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Emend Intravenous-Pioglitazone and metformin
- Emend Intravenous-Pioglitazone and Metformin Extended-Release Tablets
- Emend Intravenous-Pioglitazone and Metformin Tablets
- Emend Intravenous-Pioglitazone Hydrochloride
- Emend Intravenous-Pioglitazone Tablets
- Emend Intravenous-Piperacillin
- Pioglitazone and Glimepiride Tablets-Emflaza
- Pioglitazone and Glimepiride Tablets-Emflaza (Deflazacort Oral Suspension)
- Pioglitazone and Glimepiride Tablets-Emflaza (Deflazacort Tablets)
- Pioglitazone and Glimepiride Tablets-Emicizumab
- Pioglitazone and Glimepiride Tablets-Emicizumab-kxwh
- Pioglitazone and Glimepiride Tablets-Emicizumab-kxwh Subcutaneous